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Non-Hodgkin lymphomas are common in dogs, and their annual incidence has been 
estimated as 13–107 per 100,000 dogs per year (Dorn et al., 1968; Dobson et al., 2002; 
Mellanby et al., 2003). Lymphoma accounts for approximately 80% of hematopoietic 
malignancies in dogs (Dorn et al., 1968). In human medicine, World Health Organization 
(WHO) classification of lymphoid neoplasms has been used to distinguish the indolent 
subgroups from the major aggressive subgroups (The Non-Hodgkin's Lymphoma 
Classification Project., 1997). Clinical features in each patient are quite diverse; therefore, 
lymphoma is composed of multiple disease subtypes in humans. Therapeutic trials focusing 
on each subtype have been carried out to identify more effective treatment modalities (The 
Non-Hodgkin's Lymphoma Classification Project., 1997; Armitage., 2012). In veterinary 
medicine, canine lymphoma is also found to include diverse range of its subtypes and the 
World Health Organization (WHO) classification of hematopoietic tumours of domestic 
animals was published in 2002 (Valli et al., 2002). The clinical features of various lymphoma 
subtypes were found to be remarkably variable as with human lymphomas and a recent study 
on a large number of dogs with lymphoma showed the subtype categorization as well as their 
prognoses after treatment (Valli et al., 2013). Further efforts to determine the most effective 
therapeutic strategy in each subtype of lymphoma are considered to be necessary for 
obtaining better prognoses and outcomes in each subtype of canine lymphomas showing 
different histopathological characteristics.   
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Valli et al reported architectural features, immunophenotypes, and molecular clonality 
findings for canine indolent lymphoma and proposed a new subtype named nodal paracortical 
(T-zone) lymphoma (TZL), which showed clinically indolent behavior with long survival 
despite generalized lymphadenopathy and limited clinical response to chemotherapy (Valli et 
al., 2006). It was reported that the most common histopathological subtype in canine indolent 
lymphoma was TZL (62%), followed by marginal zone lymphoma (25%) in 60 dogs with 
indolent lymphoma (Flood-Knapik et al., 2013). Dogs with TZL had the longest median 
survival (622 days), although conceivably they were diagnosed in later stages of the disease 
because of the lack of signs associated with progression (Valli et al., 2013). Recently, Seelig 
et al. reported that immunophenotyping was an important tool for classification of canine 
lymphomas: all cases with CD45
-
 T-cell lymphoma could be classified as TZL (Seelig et al., 
2014). Immunophenotypic features in conjunction with the histopathological findings would 
facilitate the subtype classification and understanding its pathophysiology. 
In humans, Interleukin (IL)-2 receptor alpha chain (CD25) expression has been found in 
various types of lymphoproliferative diseases such as adult T-cell leukaemia/lymphoma 
(ATL), hairy-cell leukaemia (HCL), chronic lymphocytic leukaemia (CLL), acute 
lymphoblastic leukaemia (ALL), Hodgkin’s lymphoma (HL), and non-Hodgkin’s lymphoma 
(NHL) (Sheibani et al., 1987; Tesch et al., 1993; Burton et al., 1994; Nakase et al., 1994a, b; 
Horiuchi et al., 1997). CD25 is a component of interleukin-2 receptor and has two other 
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subunits, beta and gamma chains. Heterotrimerization of these subunits leads to formation of 
a receptor with high-affinity binding to IL-2, which induces proliferation and maturation of 
lymphocytes (Lowenthal et al., 1985). Therefore, it was hypothesized that CD25 on the 
tumour cells played some biological role in tumorigenesis or resistance to chemotherapeutic 
drugs (Kuhn et al., 2005). Moreover, CD25 could be a new diagnostic or prognostic marker 
as well as the therapeutic target in lymphoid malignancies with CD25 expression (Waldmann 
et al., 2007; Olejniczak et al., 2008; Fujiwara et al., 2013). As shown in humans, canine 
CD25 is known as an important marker of activated lymphocytes (Helfand et al., 1992; 
Galkowska et al., 1996). Although expression of CD25 messenger RNA (mRNA) has also 
been reported in canine lymphoma and leukaemia (Dickerson et al., 2002), the relationships 
between its expression and pathophysiology or prognosis have not been well understood. 
In general, dogs with lymphoma are treated by combination chemotherapy, because many 
of the canine lymphoma subtypes respond to chemotherapy (Garrett et al., 2002; Ettinger et 
al., 2003). CHOP-based protocols, using cyclophosphamide, doxorubicin 
(hydroxydaunorubicin), vincristine (oncovin), and prednisolone, have been used as a standard 
therapy for canine lymphoma, and the complete response (CR) rates and initial remission 
durations were reported to be 60–90% and 8–12 months, respectively (Keller et al., 1993; 
Myers et al., 1997; Zemann et al., 1998). Various CHOP-based protocols have been 
introduced and remarkable improvement in terms of the response rate, survival time, and 
7 
 
disease-free duration has been obtained since the CHOP-based protocol had been introduced 
for the treatment of canine lymphoma. In one of the standard CHOP-based protocols, a 
6-month modified version of the University of Wisconsin (UW)-Madison chemotherapy 
protocol (UW25), remission rate as high as 94.2% and median survival time as long as 397 
days were reported (Garrett et al., 2002). Many of the canine lymphoma patients can achieve 
remission after combination chemotherapy; however, they eventually relapse or acquire drug 
resistance (Garrett et al., 2002; Sorenmo et al., 2010). Therefore, new monitoring systems to 
predict the relapse or drug resistance are warranted.  
In veterinary medicine, measurement of the sizes of lymph nodes and tumor masses after 
chemotherapy has been used to indicate the response to the treatment. An objective marker to 
evaluate the amount of tumor cells burden in the body has been required to precisely compare 
the efficacy of different chemotherapeutic protocols. Recently, a minimal residual disease 
(MRD) quantification system for canine lymphoma to detect residual malignant cells that 
have escaped from anti-tumor therapies has been reported (Yamazaki et al., 2008). It was 
demonstrated that an increase in MRD could be detected before clinical relapse in dogs with 
lymphoma (Sato et al., 2011); however, sequencing of the rearranged antigen receptor genes 
and synthesis of patient-specific primers and probe were needed to measure the MRD in these 
studies (Yamazaki et al., 2008; Sato et al., 2011)  
In lymphoid malignancies in humans, soluble form of CD25 is shown to be released 
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directly from the surface of neoplastic cells constitutively expressing CD25 and its serum 
level has been found to reflect the prognosis. The level of soluble interleukin-2 receptor 
(sIL-2r) has been measured in serum samples from the patients with various type of lymphoid 
malignancies such as HL, NHL, HCL, and ATL (Rubin et al., 1990; Tesch et al., 1993; 
Nakase et al., 1994a). Several reports revealed the relation between serum sIL-2r 
concentration and the clinical outcome (Kono et al., 2000; Niitsu et al., 2001; Oki et al., 
2008; Ennishi et al., 2009; Morito et al., 2009). Therefore, serum sIL-2r concentration can be 
used as a biological marker to indicate clinical behavior and the prognosis in human NHL. 
However, there has been no study to examine the presence of serum sIL-2r in dogs with 
lymphoma so far. 
A series of studies in this thesis were carried out to investigate the expression of CD25 
and measurement of sIL-2r in relation to the prognosis and clinical behavior in canine 
lymphoid tumours. The study in Chapter 1 was carried out to understand the clinical and 
histopathological features of TZL in conjunction with the expression of CD25. The study in 
Chapter 2 was aimed to evaluate CD25 expression in various canine lymphoid tumour cells 
and its relationship with their prognosis. Based on the results from Chapters 1 and 2, Chapter 
3 was carried out to detect the presence of sIL-2r in canine serum and quantify its 
concentration using a newly developed sandwich enzyme-linked immunosorbent assay 
(ELISA) system especially in dogs with high-grade B-cell lymphoma that underwent a 
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CHOP-based chemotherapy. 
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Clinical and histopathological evaluation of  
16 dogs with T-zone lymphoma 
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Abstract 
 
Clinical and histopathological characteristics of 16 dogs with nodal paracortical (T-zone) 
lymphoma (TZL) were evaluated. At initial examination, generalized lymphadenopathy was 
found in all dogs, and peripheral lymphocytosis was found in 10 of the 16 dogs. At initial 
diagnosis or during the disease course, 8 dogs (50%) were affected with demodicosis. 
Immunohistochemical analysis for CD3, CD20, and CD25 was performed for 6 dogs with 
TZL; the tumor cells were positive for CD3 and CD25 and negative for CD20. Median 
overall survival time was 938 days. A watchful waiting approach was adopted for 6 cases 
(38%), and 5 of the 6 dogs were still alive at the end of follow-up. The clinical course of TZL 
in dogs is generally indolent; however, many cases develop a variety of infectious and other 
neoplastic diseases after the diagnosis of TZL. 
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Introduction 
 
Non-Hodgkin lymphomas are common in dogs, and their annual incidence has been 
estimated as 13–107 per 100,000 dogs per year (Dorn et al., 1968; Dobson et al., 2002; 
Mellanby et al., 2003). In 2002, the World Health Organization (WHO) classification of 
hematopoietic tumors of domestic animals was published (Valli et al., 2002). In 2006, Valli et 
al reported architectural features, immunophenotypes, and molecular clonality findings for 66 
cases of canine indolent lymphoma and proposed a new subtype named nodal paracortical 
(T-zone) lymphoma (TZL), which showed clinically indolent behavior with long survival 
despite generalized lymphadenopathy and limited clinical response to chemotherapy (Valli et 
al., 2006).
 
In the Kiel classification, the lymphoma subtype corresponding to TZL was shown 
to have cytological characteristics of small clear cell (Fournel-Fleury et al., 1997). 
It was reported that the most common histopathological subtype in canine indolent 
lymphoma was TZL (61.7%), followed by marginal zone lymphoma (25%) in 60 dogs with 
indolent lymphoma (Flood-Knapik et al., 2013). Dogs with TZL had the longest median 
survival (622 days), although conceivably they were diagnosed in later stages of the disease 
because of the lack of signs associated with progression (Valli et al., 2013). Recently, 
immunophenotyping has been considered an important tool for classification of canine T-cell 
lymphoma (TCL), which is clinically and histologically heterogeneous. Seelig et al 
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demonstrated immunophenotyping assessment for dogs with TCL by flow cytometric 
analyses using several types of antibodies and reported that all cases with CD45
-
 TCL could 
be classified as TZL (Seelig et al., 2014). 
In human medicine, WHO classification of lymphoid neoplasms has been used to 
distinguish the indolent subgroups from the major aggressive subgroups (The Non-Hodgkin’s 
lymphoma Classification Project., 1997). The clinical features of various lymphoma subtypes 
were found to be remarkably variable. Therapeutic trials focusing on these specific subgroups 
have been carried out to identify more effective treatment options (The Non-Hodgkin’s 
lymphoma Classification Project., 1997; Armitage et al., 2012). In veterinary medicine, a 
recent study showed the subtype categorization of 456 dogs with lymphoma and reported 
their prognoses after a variety of treatment protocols (Valli et al., 2013). Further efforts to 
determine the most effective therapeutic strategy in each subtype of lymphoma are 
considered to be necessary for obtaining better prognoses and outcomes in canine lymphoma.  
The aim of the present study is to understand the clinical and histopathological features in 
16 dogs with TZL, which seems to have distinct clinical characteristics and disease course 
compared with the more common high-grade lymphomas in dogs.  
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Materials and methods 
 
Criteria for selection of cases 
A retrospective study was performed at the Veterinary Medical Center of the University 
of Tokyo (UTokyo-VMC) from May 2004 through November 2012. Medical records were 
reviewed to identify dogs with TZL that presented to the UTokyo-VMC during the period. 
Cases included in this study were those involving 25 dogs that were histologically diagnosed 
with multicentric TZL. Of the 25 cases, 9 were excluded for the following reasons: 6 cases 
for incomplete clinical data and 3 cases for inadequate biopsy procedures instead of the 
resection of a whole lymph node. All nodal biopsy specimens were reviewed by a single 
pathologist blinded to clinical information during the slide-review process. All cases were 
also required to have adequate follow-up information from initial diagnosis. 
 
Immunological subtypes 
To examine the clonal expansion of the cells and the cell lineage, polymerase chain 
reaction (PCR) for antigen receptor gene rearrangement (PARR) and immunohistochemistry 
were employed. For the detection of clonal rearrangement of IgH and TCRγ genes, PCR 
analyses were performed for 8 cases. DNA samples were extracted from primary lymphoma 
cells obtained by fine needle aspiration or biopsy. PARR was performed as described 
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previously (Burnet et al., 2003; Valli et al., 2006). 
Immunohistochemistry for CD3 and CD20 was employed to determine the tumor 
phenotype for 16 cases in this study. Anti-CD3 (polyclonal rabbit anti-human A0452; DAKO, 
Glostrup, Denmark; 1:50 dilution) and anti-CD20 (polyclonal rabbit anti-human RB-9013-P; 
Thermo Fisher Scientific, Waltham, MA; 1:400 dilution) antibodies were used as primary 
antibodies. Moreover, immunohistochemical analysis using anti-CD25 (monoclonal mouse 
anti-human, clone 4C9; Thermo Fisher scientific, Waltham, MA; 1:40 dilution) antibody was 
performed for 6 dogs with TZL.  
Routine protocols of immunohistochemistry were performed on 4-μm sections of 
formalin-fixed and paraffin-embedded tissues. These sections were dewaxed and rehydrated 
through graded alcohols to water, and antigen retrieval was performed in 1% citrate buffer 
solution (pH 6.0) in the autoclave at 120 °C for 15 min. Endogenous peroxidase was 
inactivated by 1% hydrogen peroxide in methanol for 30 min, and blocking was processed by 
8% skim milk in Tris-buffered saline (TBS) for 40 min. The slides then were incubated 
overnight at 4 °C with a panel of primary antibodies directed to CD3, CD20, and CD25. 
Negative and positive control sections also were incubated at this stage. After all slides were 
washed for 15 min in TBS, EnVision + Dual Link System-HRP for CD3, CD20, and CD25 
was applied for 45 min at room temperature. After the slides were washed for 15 min, binding 
of the antibody was visualized using 3,3′-diaminobenzidine (DAB) as a chromogen, and 
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slides were counterstained in Mayer’s hematoxylin.  
 
Clinicopathological characteristics 
Medical records of the cases were reviewed to study clinicopathological characteristics. 
Age, sex, breed, physical examination features, the complete blood cell count profile at the 
time of diagnosis, concomitant illness, and survival time were reviewed. Staging was based 
on the WHO clinical stage criteria for canine lymphomas (Withrow et al., 2007). In addition, 
dogs were assigned to substage categories ‘‘a’’ (without systemic signs of illness) or ‘‘b’’ 
(with systemic signs of illness) (Withrow et al., 2007).   
Sizes of the peripheral lymph nodes were measured with slide calipers, and the sum of the 
longest diameter for the target lesions (up to 5 nodes) was calculated (Vail et al., 2010).
 
All 
cases were divided into 4 groups according to treatment: dogs treated with (1) CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisolone)-based protocols; (2) MP 
(melphalan and prednisolone); (3) prednisolone alone; or (4) no chemotherapy. Owners or 
referring veterinarians were contacted when the information of the treatment or outcome in 
the medical record was incomplete. 
 
Statistical analysis 
Overall survival time (OST) and lymphoma-specific survival time (LSST) were 
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calculated by Kaplan-Meier statistics for 16 cases with TZL. For both OST and LSST 
calculations, dogs were censored if they were still alive or lost to follow up. OST was 
measured from the day on which dogs were newly diagnosed as having TZL to the date of 
death as a result of any cause. LSST was defined as the time from the day on which dogs 
were newly diagnosed with TZL to the date of death from TZL. Dogs that died due to causes 
not likely associated with lymphoma (e.g., progression of concomitant malignant tumors, 
cardiac disease) were censored. 
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Results 
 
Characteristics of the dogs with TZL 
Sixteen dogs diagnosed with TZL included the following breeds: 9 Golden Retrievers 
(56%), 3 Shih Tzu (19%), and 1 case each of Cavalier King Charles Spaniel, Maltese, 
Pembroke Welsh Corgi, and mixed breed. The median age was 8 years (range: 6–11 years), 
and the sexes were as follows: 2 males, castrated; 4 females, spayed; 7 males, intact; and 3 
females, intact.  
 
Clinical conditions and complete blood cell count at diagnosis 
All of the 16 dogs had generalized lymphadenopathy, primarily including submandibular, 
superficial cervical, axillary, inguinal, and popliteal lymph nodes. Splenomegaly and/or 
hepatomegaly were found in 8 of the 16 dogs. Cutaneous lesions were found in 7 dogs: 3 
cases with demodicosis, 2 with pyoderma, 1 with lipoma, and 1 with otitis externa. Four dogs 
were found to have pale mucous membranes. Of the 16 cases, only 3 cases showed systemic 
symptoms such as a reduction in activity and appetite (2 cases), and weight loss (1 case). In 
the WHO clinical staging, 10 cases (63%) were shown to have a large number of typical 
“clear cells” (as observed in fine-needle aspiration [FNA] samples of the lymph node) in 
peripheral blood, and thus were classified into stage V. Of the 16 cases, 13 cases (81%) were 
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assigned into substage “a.” Consequently, WHO clinical stages and substages of the 16 dogs 
were IIa (n = 1), IIIa (n = 3), IVa (n = 1), IVb (n = 1), Va (n = 8), and Vb (n = 2). 
In complete blood cell count at initial diagnosis, of the 16 dogs, 2 (13%) had mild anemia 
(hematocrit [Hct] 0.30, 0.34). Ten cases (63%) had lymphocytosis (5,230–19,200/μl) 
containing lymphoid cells characterized as “clear cells” in Kiel classification, in the 
peripheral blood (Fournel-Fleury et al., 1997). Four cases had thrombocytosis (511,000–
845,000/μl) above the laboratory’s reference range. Information regarding signalment, WHO 
clinical stages, substages, and clinical information is presented in Table 1–1. 
 
Cytological and histopathological characteristics 
The mature lymphoid cells similar to “clear cells” that increased in the peripheral blood in 
10 cases had small- to medium-sized nuclei (an average size of 1 to 1.5 red blood cells) 
showing densely stained chromatin and relatively abundant clear cytoplasm (Fig 1–1. A, B). 
Such lymphoid cells were also found in the peripheral blood, even in cases without 
lymphocytosis, although these cases were not assigned to stage V in the WHO clinical 
staging system.  
In the cytological specimens obtained from enlarged peripheral lymph nodes, TZL was 
composed of small- to medium-sized lymphocytes with clear cytoplasm sometimes showing 
extension to form hand-mirror or tear-drop image (Fig 1–2. A–D). The nuclei had little 
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internal detail and were small to medium in size, showed densely stained chromatin, and 
sometimes had sharp shallow indentations. Mitotic figures were quite rare. 
Histopathologically, neoplastic cells were small to intermediate in size, and they 
expanded from the paracortex to the cortex and medullary cords. The capsule of the lymph 
node was at least focally thinned, although perinodal tissue was not involved. Fading follicles 
and germinal centers were found and tended to be peripheralized by the expanding population 
of neoplastic T cells (Fig 1–3. A, B). 
 
PARR and immunohistochemistry 
Of 16 dogs, 8 underwent genetic clonality analyses. Four of the 8 dogs with T-zone 
lymphoma showed monoclonal rearrangement of TCRγ. One dog showed clonal 
rearrangement of both IgH and TCRγ. In the other 3 dogs, clonal rearrangement of IgH or 
TCRγ was not detected by PARR. 
Immunohistochemical analysis for CD3 and CD20 was performed for 16 dogs. In 15 dogs 
(94%), the majority of the lymphoid cells on the nodes were immunopositive for CD3. In 1 
dog (6%), the tumor cells were double-positive for CD3 and CD20. The results regarding 
immunohistological phenotype and PARR are presented in Table 1–1. 
Immunohistochemical analysis for the CD25 antigen was performed for 6 dogs with TZL 
that were positive for CD3, as confirmed by immunohistochemistry. In all 6 cases, 
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CD25-positive cells were found in accordance with CD3-positive and CD20-negative 
neoplastic cellular localization. Among the expanding population of neoplastic cells in the 
paracortical regions of nodes, almost all the cells were strongly immunopositive for CD25 
(Fig 1–4. A−F). 
 
Complications observed in the 16 dogs with TZL  
Eleven (69%) of 16 cases had complications during the disease course by follow-up 
(181–1,662 days; median, 841 days): demodicosis (8 cases), cystitis (4 cases), pyoderma (4 
cases), otitis externa (3 cases), corneal ulcer (2 cases), conjunctivitis (2 cases), epulis (2 
cases), mast cell tumor (2 cases), sebaceous carcinoma (1 case), pyelonephritis (1 case), 
chronic renal failure (1 case), melanoma (1 case), hemangiosarcoma (1 case), and 
meningioma (1 case). Three cases (19%) had a benign skin tumor (lipoma, papilloma, and 
cutaneous plasmacytoma) and there were no complications in 5 cases (31%) (Table 1–2). 
 
Treatment and response to treatment 
All cases were divided into 4 groups according to the treatment: dogs treated with [1] 
CHOP-based protocols (cyclophosphamide, doxorubicin, vincristine and prednisolone) (2 
cases); [2] MP (melphalan and prednisolone) (6 cases); [3] prednisolone alone (2 cases); and 
[4] no chemotherapy (6 cases) (Table 1–1).  
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Chemotherapy with a CHOP-based protocol was conducted for 2 cases, because these 
dogs were found at the initial visit to have respiratory distress due to the lymphadenopathy. A 
follow-up of response to therapy was conducted for the 2 cases. After the treatment, 1 case 
attained a partial remission (PR); however, the other case did not respond to CHOP-based 
protocol. 
Treatment with MP protocol was conducted for 6 cases, because of respiratory distress 
from enlargement of nodes (2 cases) and progressive lymphocytosis in the peripheral blood 
(4 cases). Of the 6 cases, 5 attained PR and 1 achieved CR. Prednisolone alone was 
administered for 2 cases. One case achieved PR, but the other did not show any response. 
Watchful waiting was selected for 6 cases, because they did not show any symptoms 
caused by lymphoma during the follow-up period. Although these dogs did not receive any 
chemotherapy, the lymph node sizes were found to wax and wane for the observation period 
(10.7–37.1 months, median 26.2 months). One case developed diffuse large B-cell lymphoma 
(DLBCL) 37.1 months after the diagnosis of TZL.  
  
Prognostic analyses 
The median OST was 938 days, and the median LSST was not calculated because 
lymphoma-related death was found in only 3 dogs, and the number did not exceed half (Fig 
1–5). One of the 3 dogs had respiratory distress from enlargement of nodes, and the other 2 
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dogs had disseminated intravascular coagulation (DIC) associated with progression of 
lymphoma. All 3 dogs that died of the progression of lymphoma received chemotherapy with 
CHOP-based protocol or MP protocol. Of the 16 dogs with TZL, 8 dogs died of any reason 
by the end of the follow-up duration. Cause of death other than lymphoma included 
metastasis of sebaceous carcinoma (1 dog), hemangiosarcoma (1), IMHA plus IMT (1), 
congestive heart failure (1) and melanoma (1).  
A case that developed DLBCL after the onset of TZL died of the progression of DLBCL 
45.8 months after the initial diagnosis of TZL. The dog was treated with CHOP protocol but 
was unresponsive to the chemotherapeutic agents. In the prognostic analyses, the case was 
included in the OST group and censored at onset of DLBCL. 
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Discussion 
 
In this study, I evaluated the clinical and histological characteristics of 16 dogs with TZL 
and demonstrated that 10 cases with TZL were found to be in advanced clinical stage (stage 
V) at time of the initial diagnosis; however, 8 of these dogs retained good general conditions 
and 6 of 16 dogs with TZL showed long-term survival (10.7–37.1 months, median 26.2 
months) even without any chemotherapy. 
At the initial diagnosis or during the disease course, many cases were found to be affected 
with demodicosis or experienced the infectious diseases associated with mucocutaneous 
lesions. The peripheral lymph nodes biopsied from the 16 cases in this study showed 
characteristic histological appearances as reported by Valli et al (Valli et al., 2006; 2011). 
Moreover, immunohistochemistry revealed that the tumor cells of canine TZL were strongly 
positive for CD25.  
Golden Retrievers and Shih Tzu accounted for three-fourths of all breeds evaluated, and 
other breeds included in the study were Cavalier King Charles Spaniel, Maltese, Pembroke 
Welsh Corgi, and mixed breed. It might be possible that TZL occurs with elevated frequency 
in Golden retrievers and Shih Tzu, as described in the previous reports (Flood-Knapik et al., 
2013; Seelig et al., 2014). In this study, the median age at the time of diagnosis was 8 years 
(range: 6–11years). A previous study showed that the median age of 10 dogs with TZL was 
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8.9 years (Valli et al., 2006). Age of the dogs that developed TZL is conceivably similar or 
slightly older than that of dogs with lymphomas in general (Valli et al., 2013). 
At the initial visit, generalized lymphadenopathies in more than 4 regions of the 
peripheral lymph nodes were found in all of the 16 cases in this study. Demodicosis was 
found frequently, occurring in 8 cases (50%) throughout the observation period. A previous 
report showed that almost 10% of canine cases with TZL had demodex infection at diagnosis 
(Flood-Knapik et al., 2013); however, many more cases with TZL in the study developed an 
infection of demodex at time of initial diagnosis (3 cases, 19 %) and during the treatment (8 
cases, 50%). Demodex canis is normally present in dog skin but it has been assumed that 
immune dysfunctions and genetic disorders cause overgrowth of demodex in canine patients 
(Barriga et al., 1992; Sarkar et al., 2004). Humans undergoing chemotherapy have been 
shown to have an increased incidence of demodex infestation (Seyhan et al., 2004; Herron et 
al., 2005). Considering that many dogs with TZL developed demodicosis, canine TZL could 
be one of the important underlying diseases for the development of canine demodicosis. The 
immune abnormalities might be associated with the development of TZL and lead to a 
frequent occurrence of demoicosis. When peripheral lymphadenopathy is found in the 
presence of dermatologic problems, differentiation between hyperplastic/inflammatory and 
neoplastic changes should be made. Diagnosis as TZL should be made not just by cytology 
but by histopathological examination in order to discriminate accurately between neoplastic 
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proliferation and hyperplasia by cutaneous lesions. PARR also could be used for the 
demonstration of the clonal antigen of the lymphoma cells. 
Immunohistochemically, the neoplastic cells of 6 cases with TZL examined were 
intensely positive for CD25. It has been known that heterotrimerization of interleukin-2 
receptor α, β, and γ chains leads to high-affinity binding for IL-2 and IL-2/IL-2R complex 
and has an important role in controlling proliferation and differentiation of immune system 
cells (Lowenthal et al., 1985). In humans, previous reports have shown that CD25 expression 
is found in several types of leukemia or malignant lymphoma, including Hodgkin’s 
lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), which express CD25 antigen in a 
great proportion of cases (Tesch et al., 1993; Nakase et al., 1994a). The complete biological 
role of IL-2Rα expression in tumors is unclear, although IL-2Rα can stimulate tumor cell 
proliferation (Strauchen et al., 1987; Peuchmaur et al., 1990; Tsilivakos et al., 1994). It has 
been reported that particular hematological tumors highly express the membranous CD25 
forming an important phenotypic trait that could be a therapeutic target molecule (Sheibani et 
al., 1987; Waldmann et al., 1993; Horiuchi et al., 1997). A recent study revealed that canine 
TZL was associated with loss of CD45 expression, and CD45-negative cells expressed CD25 
by flow cytometry analysis (Seelig et al., 2014). A large amount of CD25 expression on 
canine TZL cells might have some influence on proliferation of lymphoma cells or status of 
host immunity that leads to demodicosis in the dogs with TZL. It is important to learn more 
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about aberrant phenotypes in canine lymphomas, not only for accurate diagnostic information 
but also for the study of the pathophysiology of canine lymphoma. 
In our study, of the 16 dogs, only 3 dogs died of lymphoma (TZL) at the end of the 
follow-up duration. All of them were treated with CHOP-based chemotherapy or MP protocol. 
Although the number of dogs treated with chemotherapy was small, response rates for dogs 
treated with CHOP-based chemotherapy or MP protocol were 50% and 100%, respectively. 
In dogs treated with prednisolone alone or those who did not undergo chemotherapy, there 
were no cases of death from progression of TZL. A previous report concluded that 
combination chemotherapy seemed to be less effective in dogs with TZL, compared with that 
of more aggressive lymphomas (Valli et al., 2007). It was also reported that systemic 
chemotherapy such as CHOP-based chemotherapy did not make a difference in improvement 
of outcome, and thus watchful waiting may be a reasonable approach in the early phase of the 
disease (Flood-Knapik et al., 2013). The findings from this study also concluded that 
therapeutic intervention based on aggressive chemotherapy was not necessarily required for 
all dogs with TZL. Moreover, MP protocol could be an effective and reasonable approach in 
terms of response rate and fewer side effects, if chemotherapy is required.  
Clinical features associated with TZL were characterized in most cases by systemic 
generalized lymphadenopathy, splenomegaly and/or hepatomegaly, lymphocytosis, or 
reduction in activity. There have been no criteria for initiation of treatment and therapy 
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protocols, therefore chemotherapy was started for the cases with conceivable disease-related 
symptoms such as extreme fatigue, occurrence of anemia and/or thrombocytopenia, 
progressive lymphocytosis, or massive or progressive splenomegaly or lymphadenopathy in 
this study. This study included only a small number of cases. Therefore, further studies are 
required to clarify the optimal timing for the initiation of chemotherapy for canine TZL.  
A watchful waiting approach was made for 6 (38%) of 16 cases in the study. During the 
clinical course, most cases retained a good health performance with repeated regression and 
swelling of lymph nodes for a long time, and no cases experienced the lymphoma-related 
death by the end of follow-up. It could be suggested that watchful waiting may be a 
reasonable approach for a proportion of dogs with TZL, especially for dogs without problems 
in general conditions and blood cytopenias.  
In conclusion, TZL is a characteristic subgroup of lymphoma in dogs. Dogs with TZL 
show an indolent clinical course; however, it may be difficult to achieve a complete remission 
even if using chemotherapy. Special attention is needed to consider the diagnosis and 
treatment modalities when a dog is suspected to have TZL. 
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Fig 1–1. Neoplastic cells in PBMC. 
(A) TZL cells are small or intermediate lymphocytes, and the cytoplasm is more abundant 
than that in normal lymphocytes and very lightly stained. × 1000. 
(B) The nuclei are relatively uniform in size and about 1 to 1.5 red blood cells in diameter. 
The cytoplasm is abundant and has indentations. Wright-Giemsa stain, × 1000. 
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Fig 1–2. Neoplastic cells in lymph node.  
(A) Cells with nuclei only slightly larger than red blood cells and sharp shallow nuclear 
indentation. The cytoplasm in most neoplastic cells is more abundant than normal small 
lymphocytes. × 1000. 
(B) Cells with small nuclei and dense chromatin pattern. The cytoplasm is small or moderate 
in volume and clear. × 1000. 
(C) Cells with dense chromatin pattern and highly extended cytoplasm. The nuclei have sharp 
shallow indentations and little internal detail. The nucleoli are inapparent. × 1000. 
(D) Cells with small central nucleoli and abundant clear cytoplasm. Mitoses are not present in 
most fields. Wright-Giemsa stain, × 1000. 
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Fig 1–3. The histological features of canine TZL.  
(A) Neoplastic lymphocytes expand in the paracortex and are peripheralizing the fading 
lymphoid follicles. Hematoxylin and eosin (H&E) stain. × 40. 
(B) Neoplastic cells are small to intermediate in size. The nuclei are small and have sharp 
shallow indentations. Some nuclei have small central nucleoli. H&E stain. × 1000.  
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Fig 1–4. The immunohistochemical features of canine TZL.  
(A) Neoplastic T cells in the paracortex are uniformly immunopositive for CD3. 
Immunolabeling with anti-CD3. × 40.  
(B) Intense labeling of neoplastic T cells with CD3. The neoplastic T cells are small or 
intermediate in size. Immunolabeling with anti-CD3. × 1000. 
(C) B cells in fading lymphoid follicles are immunopositive for CD20. Follicular structures 
are pressed against the outer sinus by the expanding population of neoplastic T cells. 
Immunolabeling with anti-CD20. × 40.  
(D) Neoplastic cells in the paracortex are negative for CD20. Immunolabeling with 
anti-CD20. × 1000.  
(E)  Neoplastic cells in the paracortex are strongly immunopositive for CD25. B cells in the 
lymphoid follicles are negative for CD25. Immunolabeling with anti-CD25. × 40.  
(F) CD25-positive neoplastic cells are small to medium in size. Some cells have sharp 
shallow nuclear indentations and abundant cytoplasm. Immunolabeling with anti-CD25. × 
1000. 
A B 
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Fig 1–5. Survival curves for overall survival and lymphoma-specific survival in 16 dogs with 
TZL.  
The median OST was 938 days and the median LSST wasn’t calculated.   
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Median Range
Age (years) 8 6-11
Body weight (kg) 26.4  3.9-39.2
No of Cases %
Sex 
   Male castrated 2 13
   Female spayed 4 25
   Male intact 7 44
   Female intact 3 19
Breed 
   Golden Retriever 9 56
   Shih Tzu 3 19
   Others 4 25
Stage
   Ⅰ 0 0
   Ⅱ 1 6
   Ⅲ 3 19
   Ⅳ 2 13
   Ⅴ 10 63
Substage
   a 13 81
   b 3 19
Immunological phenotype
  T 15 94
  T, B 1 6
PARR
  Clonal rearrangement for TCRγ  gene 4 25
  Clonal rearrangement for IgH gene 0 0
  Clonal rearrangement for TCRγ & IgH genes 1 6
  Negative 3 19
  Not determined 8 50
Enlarged lymph node
  Systemic 16 100
  Local 0 0
Clinical symptom
  Enlargement of spleen or liver 8 50
  Cutaneous lesion 7 44
  Pale mucous membranes 4 25
  Reduction in activity and appetite 2 13
  Respiratory distress 2 13
Hematological abnormality
  Anemia 2 13
  Leukocytosis 6 38
  Lymphocytosis 10 63
  Thrombocytosis 4 25
Chemotherapy
  CHOP-based protocol
a) 2 13
  M-P protocol
b) 6 38
  Prednisolone alone 2 13
  No treatment 6 38
a) CHOP-based protocol: cyclophosphamide, doxorubicin, vincristine, and prednisolone.
b) M-P protocol: melphalan and prednisolone.
Table 1–1. Profiles of 16 dogs with T-zone lymphoma. 
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No of cases %
  Demodicosis 8 50
  Cystitis 4 25
  Pyoderma 4 25
  Otitis externa 3 19
  Corneal ulcer 2 13
  Conjunctivitis 2 13
  Epulis 2 13
  Mast cell tumor 2 13
  Sebaceous carcinoma 1 6
  Pyelonephritis 1 6
  Chronic renal failure 1 6
  Melanoma 1 6
  Hemangiosarcoma 1 6
  Meningioma 1 6
  IMHA
a) 1 6
  IMT
b) 1 6
  Congestive heart failure 1 6
  Benign skin tumors
c) 3 19
a) IMHA: immune-mediated hemolytic anemia.
b) IMT: immune-mediated thrombocytopenia.
c) Benign skin tumors: lipoma, papilloma, and plasmacytoma.
Table 1–2. Concomitant illness that occurred during the observation period in 16 dogs with TZL. 
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Chapter 2 
 
Expression of interleukin-2 receptor alpha chain 
(IL-2rα) in canine lymphoid tumour cells 
and its relationship with prognosis 
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Abstract 
 
Interleukin-2 receptor alpha (CD25) expression has been reported in human lymphoid 
tumours and suggested to correlate with the prognosis. In this study, I evaluated the 
expression of CD25 in various canine lymphoid malignancies. Immunohistochemical 
analyses of the tissues from diffuse large B-cell lymphoma (DLBCL) (n=6), T-zone 
lymphoma (TZL) (n=5), and follicular lymphoma (FL) (n=2) revealed that intense CD25 
expression was observed in accordance with lymphoma cell localization. CD25 expression 
was detected in all of the TZL and FL cases, while it was variable among DLBCL cases. 
Furthermore, I evaluated CD25 expression in tumour cells by flow cytometric analysis in 29 
dogs with lymphoid malignancies, including high-grade B-cell lymphoma (n=17), TZL (n=5), 
FL (n=2), cutaneous lymphoma (n=2), and acute lymphoblastic leukaemia (ALL) (n=3). 
CD25 expression was significantly higher in dogs with high-grade B-cell lymphoma (n=17, 
mean±SD, 49.6±31.3%) or TZL (n=5, mean±SD, 80.2±10.0%), but significantly lower in 
dogs with ALL (n=3, mean±SD, 3.3±2.2%) than that in healthy dogs. In prognostic analysis 
of 15 cases with high-grade B-cell lymphoma, the progression-free survival was significantly 
shorter in CD25-high group than that in CD25-low group. The results obtained in this study 
are useful for subtype differentiation and prognostic analysis of canine lymphomas and future 
development of molecular-targeted therapy directed at CD25. 
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Introduction 
 
Interleukin (IL)-2 receptor alpha chain (CD25) is a component of IL-2 receptor and has 
two other subunits, beta and gamma chains. Heterotrimerization of these subunits leads to 
high-affinity binding to IL-2, which induces proliferation and maturation of lymphocytes 
(Lowenthal et al., 1985).  
In human medicine, CD25 expression has been reported in activated normal T cells and 
B- and T-cell neoplasms, whereas only <5% of unstimulated peripheral blood T cells were 
CD25-positive (Robb et al., 1981; Sheibani et al., 1987). Particularly intense expression of 
CD25 was observed in blast cells in adult T-cell leukaemia (ATL) or hairy-cell leukaemia 
patients (Sheibani et al., 1987; Horiuchi et al., 1997). Expression of CD25 has also been 
demonstrated in B-cell chronic lymphocytic leukaemia, acute lymphoblastic leukaemia 
(ALL) (Burton et al., 1994; Nakase et al., 1994a, b), Hodgkin’s lymphoma, and 
non-Hodgkin’s lymphoma (Tesch et al., 1993; Nakase et al., 1994a). Recently, it was 
reported that CD25 expression was associated with poor response rates and inferior 
progression-free survival (PFS) in diffuse large B-cell lymphoma (DLBCL) or follicular 
lymphoma (FL), and are expected to constitute a new prognostic marker (Fujiwara et al., 
2013, 2014).  
Similar to humans, canine CD25 is known as an important marker of activated 
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lymphocytes (Helfand et al., 1992; Galkowska et al., 1996). Although expression of CD25 
messenger RNA (mRNA) has also been reported in canine lymphoma and leukaemia 
(Dickerson et al., 2002), the relationship between its expression level and the prognosis has 
not been investigated.  
In the present study, I evaluated CD25 expression in various subtypes of canine 
lymphoma and ALL by using immunohistochemistry (IHC) and flow cytometry (FCM). 
Furthermore, I analysed the relationship between CD25 expression and the prognoses for 
dogs with high-grade B-cell lymphoma.  
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Materials and methods 
 
Samples for IHC 
Thirteen dogs with enlarged peripheral lymph nodes who were referred to the Veterinary 
Medical Center of the University of Tokyo, or whose tissue samples were subjected to 
histopathological examination at North Lab, were diagnosed as DLBCL (n=6), TZL (n=5), 
and FL (n=2) based on the histopathological findings of the biopsy specimens by referring 
World Health Organization (WHO) histological classification system for haematopoietic 
tumours of domestic animals (Valli et al., 2011). These tissue samples were further subjected 
to IHC to examine the expression of CD25. As controls, lymph node specimens from seven 
healthy dogs and six dogs with reactive lymphadenopathy were also subjected to this 
analysis.  
 
IHC 
Sections of formalin-fixed paraffin-embedded tissues (4 μm) were prepared using the 
following protocol. The sections were de-waxed, rehydrated, and subjected to antigen 
retrieval in 1% citrate buffer solution (pH 6.0) in an autoclave at 120°C for 15 min. 
Endogenous peroxidase was inactivated by 1% hydrogen peroxide in methanol for 30 min, 
and blocking was processed by 8% skim milk in Tris-buffered saline (TBS) for 40 min. The 
41 
 
slides were then incubated overnight at 4°C with the panel of anti-CD3 (polyclonal rabbit 
anti-human A0452; DAKO, Glostrup, Denmark; 1:50 dilution), anti-CD20 (polyclonal rabbit 
anti-human RB-9013-P; Thermo Fisher Scientific, Waltham, MA, USA; 1:400 dilution), or 
anti-CD25 (monoclonal mouse anti-human, clone 4C9; Thermo Fisher Scientific; 1:40 
dilution). After washing for 15 min in TBS, slides underwent reactions with EnVision + Dual 
Link System-HRP (DAKO) for 45 min at room temperature, were washed for 15 min, and 
visualized using 3,3’-diaminobenzidine (DAB) as a chromogen. Slides were counterstained in 
Mayer’s hematoxylin.  
In six DLBCL cases, the number of CD25-positive lymphoma cells was counted and 
classified into three groups: group 1 with <20% positive tumour cells, group 2 with 20–60% 
positive tumour cells, or group 3 with >60% positive tumour cells. 
 
Samples for FCM analysis  
Neoplastic cells were obtained from 29 dogs with lymphoid malignancies who were 
referred to the Veterinary Medical Center of the University of Tokyo. Samples were obtained 
from peripheral lymph nodes in 24 nodal lymphoma cases, cutaneous masses in two 
cutaneous lymphoma cases, and peripheral blood separated by Ficoll-Paque gradient 
centrifugation (Ficoll-Paque PLUS; GE Healthcare, Amersham Place, England) from three 
ALL cases at the initial diagnoses. Diagnosis was made based on clinical data and 
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cytological/histological examination of lymph-node or bone marrow in dogs with lymphoma 
and leukaemia, respectively. PCR for antigen-receptor gene rearrangement (PARR) was 
performed to determine the clonality and cell lineage of 26 lymphoma and three ALL cases. 
DNA samples of all cases were extracted from fresh samples from the lymph node, peripheral 
blood, or bone marrow. Primers and protocols for PCR analyses were described previously 
(Burnett et al., 2003; Valli et al., 2006). Twenty six dogs with lymphomas were further 
classified into subtypes of high-grade B-cell lymphoma (n=17), TZL (n=5), FL (n=2), or 
cutaneous lymphomas (n=2) according to the cytology and/or histopathology (Fournel-Fleury 
et al., 1997, 2002; Valli et al., 2006, 2011). For comparison, samples were also obtained from 
peripheral lymph nodes from seven healthy dogs and six dogs with reactive 
lymphadenopathy.  
 
FCM 
Single-color FCM was performed for the cell samples obtained from dogs with lymphoid 
malignancies. Cell suspensions were washed with staining medium (phosphate-buffered 
saline supplemented with 5% foetal calf serum) and stained with fluorescein isothyocyanate 
(FITC)-conjugated anti-canine CD25 mAb (P4A10; eBioscience, San Diego, CA, USA) for 
30 min at 4°C. Cells were washed twice and analysed with a flow cytometer (FACSCalibur; 
BD Biosciences, San Jose, CA, USA). An FITC-conjugated mouse IgG1 was used to analyse 
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the background fluorescence intensity during each analysis. Lymphoma or leukaemic cells 
were gated from the forward- and side-scatter properties. A minimum of 10,000 events in the 
gated region was collected for each sample. The obtained data were analysed using FlowJo 
software (Tree Star, Ashland, OR, USA). The percentages of CD25-positive cells were 
calculated from the isotype-matched control for each sample. 
 
Statistical analysis 
The Mann-Whitney U test was used to compare the prognosis in dogs with DLBCL 
showing different CD25 expression. PFS and overall survival (OS) were calculated according 
to the criteria proposed by the veterinary cooperative oncology group (Vail et al., 2010). PFS 
was calculated from the date of initial treatment to disease progression or death from any 
cause. OS was calculated from the date of initial treatment to death from any cause. Dogs that 
were still alive or lost to follow-up were censored at the date on which they were last known 
to be alive. PFS and OS were estimated by the Kaplan-Meier method, and the groups were 
compared by the log-rank test. The p values were two-sided and regarded as significant if p < 
0.05. Data were analysed using StatMate software version IV for windows (ATMS, Tokyo, 
Japan).  
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Results 
 
IHC for CD25 expression 
Six dogs with DLBCL, five dogs with TZL, two dogs with FL, six dogs with reactive 
lymphadenopathy, and seven healthy dogs were subjected to immunohistochemical analyses 
to examine CD25 expression.  
In seven healthy dogs and six dogs with reactive lymphadenopathy, CD25 expression was 
generally weak in both CD3-positive and CD20-positive cells, regardless of lymph node 
regions (Fig 2–1. A–D). Less than 10% of the cells in the entire lymph node field were 
CD25-positive in these dog groups. 
Next, CD25 expression was examined in the lymph nodes derived from dogs with TZL. 
In the lymph nodes from five dogs with TZL, neoplastic T cells, which are small or 
intermediate in size, expanded in the paracortex, pressing the atrophic germinal centres 
against the outer sinus. Majority of the neoplastic CD3-positive cells were shown to be 
strongly immunopositive for CD25 (Fig 2–2. A–D). 
Further, I evaluated CD25 expression in the lymph nodes of FL cases. In the two FL cases 
included in this study, the majority of CD20-positive centrocytes in the follicles were shown 
to be strongly immunopositive for CD25 (Fig. 2–3. A–D).  
Six dogs with DLBCL were also examined for CD25 expression. In all the six cases, 
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neoplastic large B cells with uniformly large nuclei and scanty cytoplasm diffusely 
proliferated in the lymph nodes as a mixture of centroblastic cells with multiple nucleoli and 
immunoblastic cells with a single central prominent nucleolus. Unlike in TZL and FL, CD25 
expression in the lymph nodes of DLBCL was variable. Two of the six cases showed 
relatively weak CD25 expression and were categorized as group 1 (<20% positive tumour 
cells; Fig 2–4. A, B). Two cases showed intermediate CD25 expression and were judged as 
group 2 (20–60% positive tumour cells; Fig 2–4. C, D), and the remaining two cases strongly 
expressed CD25 and were categorized as group 3 (>60% positive tumour cells; Fig 2–4. E, F). 
Morphological features were not different among the six DLBCL cases exhibiting various 
degrees of CD25 expression.  
 
FCM for CD25 expression 
Samples from 26 dogs with lymphoma, three dogs with ALL, six dogs with reactive 
lymphadenopathy, and seven healthy dogs were subjected to FCM. Immunological subtypes 
of tumour samples were determined by PARR. Information regarding signalment, staging at 
the initial diagnosis, and immunological phenotype is presented in Table 2–1. 
Single-color FCM was performed to evaluate CD25 expression in the lymphoid 
neoplastic cells. The percentages (mean±SD) of lymph node-derived lymphocytes that were 
CD25-positive in healthy dogs and dogs with reactive lymphadenopathy were 9.8±2.8% (n=7, 
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range: 6.4–13.8%) and 13.7±5.0% (n=6, range: 8.3–22.2%), respectively. CD25 expression 
was 49.6±31.3% (n=17, range: 0.4–97.1%) in high-grade B-cell lymphoma, 80.2±10.0% (n=5, 
range: 64.6–95.4%) in TZL, 69.4±22.3% (n=2, range: 47.1–91.7%) in FL, 73.7±16.5% (n=2, 
range: 57.2–90.2%) in cutaneous lymphoma, and 3.3±2.2% (n=3, range: 1.5–6.4%) in ALL. 
The percentages of CD25-positive cells were significantly higher in high-grade B-cell 
lymphoma and TZL, but significantly lower in ALL than those in healthy dogs (Fig 2–5). 
 
Therapeutic response and prognosis of dogs with high-grade B-cell lymphoma 
In order to examine the relationship between CD25 expression and prognosis, the clinical 
course of 15 dogs with high-grade B-cell lymphoma, who received CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisolone)-based protocols (Garret et al., 
2002), were followed for up to 919 days. Since the mean value of CD25-positive tumours 
among the 15 cases was 58.9%, the cut-off value was set to 60% in this study. Fifteen dogs 
were divided into two groups: CD25-positive cells > 60% (CD25-high) (n=7) and <60% 
(CD25-low) (n=8). Three of seven CD25-high dogs (42.9%) responded to the treatment, 
while seven of eight CD25-low dogs (87.5%) showed the response to treatment. The response 
rate was not significantly different between the CD25-high and CD25-low dogs. The median 
value of PFS was 28 days in CD25-high dogs, which was significantly shorter than that 
observed for CD25-low dogs (median: 140 days; Fig 2–6. A). Kaplan-Meier curves also 
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showed an apparently inferior OS in the CD25-high group (median: 115 days) relative to the 
CD25-low group (median: 244 days). However, there was no significant difference between 
the two groups (Fig 2–6. B).  
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Discussion 
 
IHC revealed that neoplastic lymphocytes strongly expressed CD25 in all cases of TZL 
and FL, while lymphocytes of healthy dogs and dogs with reactive lymphadenopathy weakly 
expressed CD25. However, CD25 expression was variable among DLBCL cases. In all of 
these types of lymphoma, CD25 expression was predominantly detected in malignant cells. 
The surrounding reactive lymphoid cells were negative or weakly immunopositive for CD25. 
In agreement with IHC results, FCM revealed that non-neoplastic lymphocytes of healthy 
dogs and dogs with reactive lymphadenopathy showed low CD25 expression as compared to 
lymphoma cells at the initial diagnosis.  
In several types of leukaemia or malignant lymphoma in humans, CD25 was shown to be 
expressed mainly in tumour cells (Waldmann, 1986; Sheibani et al., 1987). Participation of 
the α subunit of the IL-2R complex was shown to be necessary for the formation of the 
high-affinity IL-2 receptor in human lymphocytes (Gutgsell et al., 1994; Cassell et al., 2002). 
Since it was reported that CD25-positive lymphoma cells also produce IL-2 (Sheibani et al., 
1987; Peuchmaur et al., 1990), IL-2/IL-2R signalling might activate the proliferation of 
lymphoma cells (Olejniczak et al., 2008). In dogs, it was shown that multicentric lymphoma 
cells expressed mRNA of interleukin-2 receptor α, β, and γ chains (Dickerson et al., 2002). 
The resulting surface IL-2R on lymphoma cells had binding affinity for IL-2. Moreover, it 
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has been suggested that canine lymphoma cells expressing IL-2R might maintain their 
proliferative state through an IL-2-dependent autocrine-growth pathway (Helfand et al., 
1995). The expression of CD25 in lymphoma cells shown in this study might result in a 
high-affinity binding to IL-2 leading to lymphoma cell proliferation; however, it remains 
unknown whether IL-2/IL-2R signalling on each type of canine lymphoma is functional.  
Notably, neoplastic lymphocytes from three ALL cases (mean±SD: 3.3±2.2%) showed 
weak CD25 expression. In human ALL, CD25 expression has been demonstrated (Nakase et 
al., 1994c), with expression levels significantly lower in T-lineage ALL relative to B-lineage 
ALL (Nakase et al., 2007). In this study, the three cases of ALL were found to be of T-cell 
origin based on results of CD3 expression from FCM and clonal rearrangement of the TCRγ 
gene in PARR. Although the number of ALL dogs analysed in our study was only three, the 
results showing that canine T-ALL expressed low levels of CD25 was consistent with a 
previous study, which showed no expression of IL-2Rα mRNA in a dog with T-ALL 
(Dickerson et al., 2002). The result obtained in this study may indicate that expression of 
CD25 in canine T-ALL is different from that in canine T-cell lymphoma. 
In agreement with IHC results, FCM analysis also demonstrated that neoplastic 
lymphocytes of TZL and FL cases showed high CD25 expression. Canine cutaneous 
lymphomas also expressed high levels of CD25. In humans, high CD25 expression in 
lymphoma cells was also reported in cutaneous T-cell lymphomas (CTCL) and FL (Talpur et 
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al., 2006; Fujiwara et al., 2014). Moreover, in human CTCL, CD25 expression was more 
commonly observed in lesions from advanced patients, and high CD25 expression was 
associated with clinical tumour-node metastasis stage and histologic grade (Talpur et al., 
2006). In this study, all cases of TZL and FL were found to have systemic lymphadenopathy 
at their initial diagnosis. Therefore, CD25-postitivity might be associated with tumour-node 
metastasis stage, as is the case with human lymphoma. 
However, CD25 expression levels were variable in high-grade B-cell lymphoma 
(mean±SD: 49.6±31.3%, range: 0.4–97.1%). In human DLBCL, the rate of CD25-positive 
neoplastic cells was significantly higher than that observed for reactive lymphadenopathy. 
Similar to our results, the rates of CD25-positive cells detected by single-color FCM varied 
among human DLBCL cases (n=123; mean±SD: 27.8±30.6%) (Fujiwara et al., 2013). In 
view of the prognosis, human DLBCL was shown to be a heterogeneous group based on the 
pattern of gene expression or particular protein expression (Alizadeh et al., 2000; Hans et al., 
2004). As with human DLBCL, canine high-grade B-cell lymphoma might comprise several 
different subtypes of lymphoma. It is most likely that canine high-grade B-cell lymphoma 
could be subdivided on the basis of gene or protein expression pattern in tumour cells. 
I investigated the relationship between CD25 expression and the prognosis in dogs with 
high-grade B-cell lymphoma. PFS was significantly shorter in the CD25-high group (median: 
28 days) than that in the CD25-low group (median: 140 days). Although not significant, the 
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response rate tended to be higher in the CD25-low group than that in the CD25-high group. 
In human DLBCL patients with high CD25 expression, response rate and PFS were 
significantly inferior to those with low CD25 expression (Fujiwara et al., 2013). While the 
biological role of CD25 expression or IL-2/IL-2R signalling in canine lymphoma cells is not 
clear, the tumour cells express large amounts of CD25, which most likely induces 
proliferation through IL-2/IL-2R binding, as shown in human lymphoma. In canine 
high-grade B-cell lymphoma, strong CD25 expression might be associated with proliferation 
rates and result in a shorter PFS in CD25-high groups. Moreover, CD25 might be an 
important phenotypic trait and a novel therapeutic target molecule in particular lymphoma 
subtypes. 
In summary, I demonstrated the expression of CD25 in canine lymphoid tumours and that 
its phenotype varied between subtypes. Moreover, CD25 expression was related with the 
prognoses in high-grade B-cell lymphoma cases. The results obtained in this study contribute 
to the subtype differentiation, prognostic analysis, and future development of 
molecular-targeted therapy directed at CD25. 
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Fig 2–1. 
Immunohistochemistry to detect CD25 expression in the lymph nodes of (A, B) a healthy dog  
and (C, D) a dog with reactive lymphadenopathy. Magnification for A and C:×40; B and D:  
×1,000. 
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Fig 2–2. Immunohistochemistry of a lymph node in a dog with T-zone lymphoma.  
Immunolabeled with (A) anti-CD3, (B) anti-CD20, or (C, D) anti-CD25. Magnification for  
A–C: ×40; D: ×1,000. 
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Fig 2–3. Immunohistochemistry of a lymph node in a dog with follicular lymphoma. 
Immunolabeled with (A) anti-CD3, (B) anti-CD20, or (C, D) anti-CD25. Magnification for  
A–C: ×40; D: ×1,000. 
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B-cell lymphoma for CD25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2–4. Immunohistochemistry of three lymph node samples from dogs with diffuse large  
B-cell lymphoma.  
(A) Group 1 (CD25-positive tumour cells < 20%), (B) Group 2 (expression 20–60%), and  
(C) Group 3 (expression > 60%). Magnification for A, C, and E: ×40; B, D, and F: ×1,000. 
A B 
C D 
F 
E F 
56 
 
 
Fig 2–5. Flow cytometric analysis of the lymphoid cell samples from dogs with lymphoid  
tumours and reactive lymphadenopathy and healthy dogs for CD25. 
Lymph-node aspirates were obtained from 17 dogs with high-grade B-cell lymphoma, five 
dogs with T-zone lymphoma (TZL), two dogs with follicular lymphoma (FL), six dogs with 
reactive lymphadenopathy, and seven healthy dogs. 
Aspirates of the cutaneous masses were obtained from two dogs with cutaneous lymphoma.  
Peripheral blood mononuclear cells were obtained from three dogs with acute lymphoblastic  
leukaemia (ALL).  
Horizontal barsindicate the mean value of each group. 
* 
CD25 expression is significantly higher as compared to healthy dogs. 
p < 0.05, Mann-Whitney U test. 
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(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2–6. Kaplan-Meier plot of (A) progression-free survival and (B) overall survival in the  
CD25-high and CD25-low groups of high-grade B-cell lymphoma. 
Dogs with CD25-positive cells > 60% were categorized as the CD25-high group (n=7), and  
those with CD25-positive cells < 60% as the CD25-low group (n=8). The two groups were  
compared using the log-rank test. 
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Cases %
Sex
   Male, castrated 7 27
   Female, spayed 9 35
   Male, intact 6 23
   Female, intact 4 15
Breed
   Pembroke Welsh Corgi 7 27
   Miniature Dachshund 4 15
   Shih Tzu 4 15
   French Bulldog 2 8
   Pomeranian 2 8
   Mixed breed 2 8
   Others 5 19
WHO clinical stage
   Ⅰ 1 4
   Ⅱ 0 0
   Ⅲ 3 12
   Ⅳ 2 8
   Ⅴ 20 77
Substage
   a 19 73
   b 7 27
Hitological/cytological subtype
   High-grade B-cell lymphoma 17 65
   TZL
b
5 19
   FL
c
2 8
   Cutaneous lymphoma 2 8
   
a
 FCM, flow cytometry.
   
b
 TZL, T-zone lymphoma.
    c
 FL, follicular lymphoma.
Table 2–1. Twenty-six dogs with lymphoma used for flow cytometric analysis. 
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Chapter 3 
 
Measurement of the concentration of serum  
soluble interleukin-2 receptor alpha chain  
in dogs with lymphoma 
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Abstract 
 
Soluble interleukin 2 receptor (sIL-2r) is released directly from the surface of 
lymphocytes expressing interleukin 2 receptor alpha chain (CD25) and its serum 
concentration has been found to reflect the prognosis in human lymphoproliferative 
malignancies. In this study, I demonstrated the existence of sIL-2r in canine serum and 
developed a specific sandwich enzyme-linked immunosorbent assay (ELISA) to quantify the 
concentration of canine serum sIL-2r. Using immunoprecipitation (IP) assay, CD25 protein 
weighing approximately 45 KDa was detected in canine serum, smaller than the 
membrane-bound CD25 (approximately 55 KDa). To measure the concentration of serum 
sIL-2r in dogs, ELISA system was developed. Serum sIL-2r level was significantly higher in 
dogs with multicentric high-grade B-cell lymphoma before therapy than that in healthy dogs 
and dogs with inflammatory diseases. Serum sIL-2r concentration was also found to be 
elevated in a proportion of dogs with other lymphoma types and immune-mediated diseases. 
Changes in serum sIL-2r levels generally paralleled with the changes of lymph node size in 
dogs with high-grade B-cell lymphoma. This study demonstrated that serum sIL-2r level 
would be a marker to monitor the tumor growth and regression in canine lymphoma. 
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Introduction 
 
Interleukin (IL)-2 receptor alpha chain (CD25) is a component of IL-2 receptor (IL-2r) 
together with other subunits, beta and gamma chains. Heterotrimerization of these three 
subunits leads to high-affinity binding to IL-2, which induces proliferation and maturation of 
lymphocytes (Lowenthal et al., 1985). CD25 is shown to be a membrane-bound protein of 
approximately 55 kDa in humans and dogs (Leonard et al., 1983; Abrams et al., 2010). In 
humans, soluble IL-2 receptor (sIL-2r), which is smaller than its membrane-bound form (45 
kDa vs. 55 kDa), can be detected in the serum of healthy individuals (Rubin et al. 1985, 
1990). Elevation of the serum sIL-2r concentration has been shown in human patients with 
various lymphoid malignancies including Hodgkin’s lymphoma (HL), non-Hodgkin’s 
lymphoma (NHL), hairy cell leukemia (HCL) and adult T-cell leukemia/lymphoma (ATL) 
(Rubin et al., 1990; Tesch et al., 1993; Nakase et al., 1994a). Several reports demonstrated 
the relation between serum sIL-2r concentration and the clinical outcome in these diseases 
(Kono et al., 2000; Niitsu et al., 2001; Oki et al., 2008; Morito et al., 2009). Therefore, 
serum sIL-2r concentration has been used as a biological marker to indicate the growth of 
tumour cells as well as the prognosis in lymphoid malignancies in humans, especially in 
NHL.  
NHLs are common tumours in dogs, and their incidence has been estimated as 13–107 
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per 100,000 dogs per year (Dorn et al., 1968; Dobson et al., 2002; Mellanby et al., 2003). 
Lymphoma accounts for approximately 80% of hematopoietic malignancies in dogs (Dorn et 
al., 1968). Similar to humans, CD25 is expressed on the cell surface of T-lymphocytes 
during activation and proliferation in dogs (Helfand et al., 1992; Galkowska et al., 1996). 
Expression of CD25 messenger RNA (mRNA) has also been detected in canine lymphoma 
and leukaemia cells (Dickerson et al., 2002). Moreover, it has been suggested that canine 
lymphoma cells expressing CD25 maintain their proliferative state through an 
IL-2-dependent autocrine growth pathway (Helfand et al., 1995). In Chapter 1 in this thesis, 
strong expression of CD25 was revealed in the tumour cells derived from T-zone lymphoma 
(TZL) in dogs. Next, in Chapter 2, CD25 expression was detected in the tumour cells 
derived from diffuse large B-cell lymphoma, follicular lymphoma (FL), and cutaneous 
lymphoma. However, there has been no study to evaluate the existence of sIL-2r in dogs so 
far. 
In this chapter, I carried out a study to examine the presence of sIL-2r in canine serum 
and quantify its concentration in canine serum using a newly developed sandwich 
enzyme-linked immunosorbent assay (ELISA) system. Moreover, sequential change of the 
serum sIL-2r concentration was examined in 4 dogs with lymphoma that had relatively high 
serum sIL-2r concentrations before chemotherapy. 
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Materials and methods 
 
Antibody production 
A rabbit polyclonal antibody (PAb) directed to a 20-amino acid peptide, 
CISESQFPDDEELQASTDAP, corresponding to the extracellular domain of canine CD25 
(Dickerson et al., 2002) was synthesized. Rabbits were immunized with the synthesized 
peptide conjugated to keyhole limpet hemocyanin together with complete Freund’s adjuvant 
(Sigma-Aldrich, St. Louis, MO). Antiserum was subjected to an affinity purification column 
(Sigma-Aldrich) with the peptide used for the immunization. The purified polyclonal 
antibody was biotinylated as indicated by the manufacturer (EZ-Link NHS-Biotin; Pierce, 
Rockford, IL) for sandwich ELISA. 
 
Sandwich ELISA 
For the sandwich ELISA, microplates (96-well) (Immuno Plate Maxisorp C96; Nunc, 
Roskilde, Denmark) were coated with 2 μg/ml mouse anti-canine CD25 mAb (P4A10; AbD 
Serotec, Kidlington, UK) diluted in 50mM carbonate buffer (pH 9.6) and incubated overnight 
at 4°C. The antibody-coated plates were then washed with PBS containing 0.05% (v/v) 
Tween 20 (PBS-T) three times. PBS containing 5% rabbit serum (Sigma-Aldrich), 2% block 
ace (DS Pharma Biomedical, Osaka, Japan) and 0.4 M NaCl was added to each well as a 
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blocking buffer. The plates were incubated for 1 hr at room temperature, and then washed 
three times with PBS-T. Recombinant canine IL-2 receptor α (rcCD25) (R&D Systems, Inc, 
Minneapolis, MN) was serially diluted 2-fold from 800 to 12.5 ng/ml in dilution buffer 
(PBS-T containing 5% rabbit serum, 0.5% block ace and 0.4 M NaCl) and used as a standard. 
Tenfold diluted canine sera (100 μl) with dilution buffer were used as samples. Plates were 
incubated at room temperature for 2 hr and then washed three times with PBS-T. Following 
the wash steps, 100 μl of 800 ng/ml biotin-conjugated rabbit anti-canine CD25 PAb diluted 
with dilution buffer was added to each well and reacted in the well at room temperature for 1 
hr. After washing three times with PBS-T, 100 μl of peroxidase-conjugated streptavidin 
(Thermo Fisher Scientific, Waltham, MA) diluted at 1:10,000 in PBS-T containing 5% rabbit 
serum was added to each well and incubated at room temperature for 1 hr in the absence of 
light. After washing three times with PBS-T, 100 μl of 3, 3′, 5, 5′-tetramethylbenzidine 
(TMB) (Nacalai Tesque, Kyoto, Japan) substrate was added to each well and incubated at 
room temperature for 20 min in the absence of light. Finally, to stop the color development, 1 
N H2SO4 was added and absorbance readings at 450 nm were measured using a microplate 
reader (Bio-Rad, Hercules, CA) to determine OD values. 
The assay was validated in determination of working range detection limit, dilution 
parallelism, spike and recovery test, and intra-assay and inter-assay variability tests. The 
detection limit and working range were determined by comparing 10 independent results of 
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blank well and wells with various concentrations of rcCD25. The concentration was 
determined as detectable if mean ± 3 SD value calculated from 10 independent results did not 
overlap with that of blank well. The dilutional parallelism was defined by the linearity of the 
serially diluted rcCD25 within the working concentration range as determined above. Spiking 
recovery was determined by adding 29.21 ng/ml and 66.59 ng/ml of rcCD25 to 3 different 
serum samples of tenfold dilution. Intra-assay variability was determined by evaluating 3 
different serum samples with different concentrations of sIL-2r in 5 independent wells. 
Inter-assay variability was determined by repeating the assay for 3 times. 
 
Serum samples for sandwich ELISA 
Canine sera were obtained from 51 dogs with lymphoma referred to the Veterinary 
Medical Center of the University of Tokyo at initial diagnosis. The dogs with lymphoma were 
classified from the anatomic forms: multicentric (n=34), alimentary (n=8), cutaneous (n=4), 
splenic (n=2), mediastinal (n=2), and skeletal (n=1) forms. Diagnosis and anatomic form 
classification were made based on the physical examination findings, diagnostic imaging, and 
cytological/histological findings of the lesions. Thirty-four dogs with multicentric lymphoma 
were divided into high-grade (n=27) or low-grade (n=7) lymphoma. Twenty-seven dogs with 
multicentric lymphoma were diagnosed as having high-grade lymphoma from the cytological 
finding of the peripheral lymph node samples obtained by fine-needle aspiration (FNA) 
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according to the updated Kiel classification (Fournel-Fleury et al., 1997). In 7 dogs with 
generalized lymphadenopathy suspected as having low-grade lymphoma from the cytology of 
the FNA aspirates showing a homogeneous population of small clear cell in the updated Kiel 
classification, resection of a peripheral lymph node was performed for the histopathological 
examination, resulting in T-zone lymphoma (TZL) in the World Health Organization (WHO) 
histological classification system for haematopoietic tumours of domestic animals (Valli et al., 
2011). PCR for antigen receptor gene rearrangement (PARR) was performed to indicate the 
clonal origin and the immunological subtype as the previous reports (Burnett et al., 2003; 
Valli et al., 2006). For comparison, sera were also acquired from 27 healthy dogs, 10 dogs 
with inflammatory diseases: bacterial gastroenteritis (4 cases) and dermatitis (6 cases) and 3 
dogs with immune-mediated diseases: polyarthritis (1 case), myasthenia gravis (1 case) and 
immune-mediated hemolytic anemia (1 case). All samples were stored at －80°C until 
analysis. 
 
Flow cytometry (FCM) 
Neoplastic cells were obtained from peripheral lymph nodes of 16 dogs with multicentric 
high-grade B-cell lymphoma by fine-needle aspiration. According to the updated Kiel 
classification (Fournel-Fleury et al., 1997), all of the 16 dogs were classified as high-grade 
B-cell centroblastic type. 
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Single-color FCM was performed for 16 dogs with high-grade B-cell lymphoma. Cell 
suspensions were washed with staining medium (PBS supplemented with 5% FCS) and 
incubated with FITC-conjugated anti-canine CD25 mAb (P4A10; eBioscience, San Diego, 
CA) for 30 min at 4°C. Cells were washed twice and analyzed with a flow cytometer 
(FACSCalibur; BD Biosciences, San Jose, CA). A control FITC-conjugated mouse IgG1 was 
used to show the background fluorescence intensity during each analysis. Lymphoma cells 
were gated from the forward and side scatter properties. A minimum of 10,000 events in the 
gated region was collected for each sample. The obtained data were analyzed using FlowJo 
software (Tree Star, Ashland, OR). The percentages of CD25-positive cells were calculated in 
comparison to the isotype matched control for each sample. 
 
Immunoprecipitation 
For detection of sIL-2r, 2 μg of anti-canine CD25 monoclonal antibody (mAb) (P4A10, 
AbD Serotec) was incubated overnight at 4°C with 50 μl of 50% Protein G Sepharose beads 
(GE Healthcare UK, Amersham Place, UK). After incubating serum samples 250μl with the 
Protein G Sepharose beads overnight at 4°C, the IgG-depleted serum samples were incubated 
with the beads-bound anti-canine CD25 mAb at 4°C for 1 hr. After washing, the beads were 
boiled with 30 μl of sample buffer (Laemmli sample buffer with 2-mercaptoethanol) and 
subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Beads 
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without mAb were served as a negative control. 
Three canine lymphoid tumour cell lines, UL-1 (Yamazaki et al., 2008), CL-1 (Momoi et 
al., 1997), and Nody-1 (Hiraoka et al., 2009) were used for immunoprecipitation. Two of 
these cell lines (UL-1 and CL-1) were cultivated in RPMI-1640 (Invitrogen, Grand Island, 
NY) supplemented with 10% fetal bovine serum (Biowest, Nuaillè, France), penicillin (100 
units/ml) and streptomycin (0.1 mg/ml) (Sigma-Aldrich). Nody-1 was cultivated in 
RPMI-1640 supplemented with 20% fetal bovine serum (Nichirei Biosciences, Tokyo, Japan), 
penicillin (100 units/ml), and streptomycin (0.1 mg/ml). All cell lines were cultivated at 37°C 
in a humidified atmosphere of 5% CO2. Total protein samples were extracted from UL-1, 
CL-1, and Nody-1 using lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1.0% NP-40, 10% 
glycerol, 1 mM EDTA).  
These samples were subjected to SDS-PAGE using 12.5% gels, and blotted onto a PVDF 
membrane (Amersham Hybond-P PVDF membrane, GE Healthcare, Little Chalfont, UK). 
The membrane was blocked with 1% skim milk in Tris–HCl buffer saline with 0.1% Tween 
20 (TBS-T). Immunoblotting was carried out with a rabbit polyclonal antibody directed to 
human CD25 (sc-664, Santa Cruz Biotechnology, Santa Cruz, CA) (Fellman et al., 2011), 
which was labeled with horseradish peroxidase (HRP) by using a Peroxidase Labeling kit-SH 
(Dojindo, Kumamoto, Japan) and diluted at 1:250. After incubating overnight at 4°C and 
washing with TBS-T, immunodetection was performed by chemiluminescence (SuperSignal 
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West Dura, Thermo Fisher Scientific) according to the manufacturer’s protocol. 
 
Follow-up evaluation during chemotherapy 
Follow-up evaluation of the serum sIL-2r concentration during treatment was carried out 
for 1 dog (Dog 1) with skeletal lymphoma and 3 dogs with multicentric high-grade B-cell 
lymphoma (Dog 2-4) who received a CHOP (cyclophosphamide, hydroxydaunorubicin 
[doxorubicin], vincristine [oncovin], and prednisolone)-based protocol, UW-25 (Garret et al., 
2002) without administration of L-asparaginase at week 1 because it did not significantly 
influence the treatment outcome (MacDonald et al., 2005). Serum samples from these 4 cases 
were obtained at initial diagnosis and during the follow-up period. Sizes of the tumour 
masses or peripheral lymph nodes were measured with slide calipers, and the sum of the 
longest diameters of the target lesions (up to 5 nodes) was calculated. Responses to the 
treatments were evaluated according to the previous report (Vail et al., 2010).  
 
Statistical analysis 
Fitting of the curves were analyzed by linear regression analysis. The Mann-Whitney 
rank sum test was used to compare the sIL-2r levels between the different dog groups. 
Correlation between cell surface CD25 expression rate and sIL-2r concentration was 
calculated by the Spearman's rank correlation coefficient. Two-sided P-values were regarded 
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as significant if less than 0.05. Data were analyzed using StatMate software version Ⅳ for 
Windows (ATMS, Tokyo, Japan).   
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Results 
 
Detection of sIL-2r in canine serum by immunoblotting  
Detection of sIL-2r in canine serum was examined by IP analysis and compared with 
membrane-bound CD25 detected in the cell lines. A single band of CD25 weighing 
approximately 55 kDa was observed by immunoblotting in CL-1 and Nody-1 but not in UL-1. 
In a canine serum sample immunoprecipitated with anti-CD25 monoclonal antibody 
(P4A10)-conjugated beads, a single band of approximately 45 kDa corresponding to sIL-2r 
was detected, which was smaller than the membrane-bound CD25 (55 kDa). No band was 
immunoprecipitated by Protein G Sepharose beads without mAb (negative control) (Fig 3–1). 
 
Construction and validation of sandwich ELISA for sIL-2r 
In the present sandwich ELISA system, anti-canine CD25 mAb (P4A10) and biotinylated 
rabbit anti-canine CD25 PAb were used as capture and detection antibodies, respectively. The 
concentrations of capture and detection antibodies were set to 2 μg/ml and 0.8 μg/ml, 
respectively. High linearity was confirmed within a concentration range from 493.8 ng/ml to 
18.3 ng/ml (R
2
 > 0.99) and no dilution effects were observed (Fig 3–2). From the 10 
independent standard curves, the lower detection limit was set to be 25 ng/ml based on 
comparison to blank wells. Adding 29.21 and 66.59 ng/ml of rcCD25 to tenfold diluted 
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canine serum from 3 dogs with various native sIL-2r concentrations, the recovery rate for this 
assay was determined to be 97–112% (Table 3–1). Intra-assay and inter-assay variabilities 
were assessed using 3 serum samples with different concentrations (mean±SD; 148.09±5.44, 
74.86±1.99, and 33.66±0.26). The coefficients of variations for 5 independent wells to assess 
intra-assay variability were 4.75, 5.39, and 12.9% in the 3 samples. Inter-assay variability 
assessed by the coefficients of variations calculated from 3 independent assays was 3.67, 2.66, 
and 0.76%. A relatively higher coefficient of variation for intra-assay variability was shown 
for the sample containing a lower concentration of sIL-2r. In contrast, inter-assay variability 
indicated that this assay had a high reproducibility (Table 3–2). These results showed that the 
sandwich ELISA developed in this study was reliable for measurement of canine serum 
sIL-2r ranging from 25 ng/ml to 493 ng/ml. 
 
Serum sIL-2r levels in 51 dogs with lymphoma 
Serum sIL-2r concentration was measured in 27 healthy dogs, 10 dogs with inflammatory 
diseases, 3 dogs with immune-mediated diseases and 51 dogs with lymphoma at initial 
diagnosis. Serum sIL-2r could be detected in 1 of 27 healthy dogs, 2 of 3 immune-mediated 
disease and 19 of 51 dogs with lymphoma. In the anatomic forms, the sIL-2r concentration 
was detectable in dogs with multicentric high-grade lymphoma (12/27, 44%), multicentric 
low-grade lymphoma (1/7, 14%), alimentary lymphoma (1/8, 13%), cutaneous lymphoma 
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(1/4, 25%), splenic lymphoma (2/2, 100%), mediastinal lymphoma (1/2, 50%), and skeletal 
lymphoma (1/1, 100%). The sIL-2r concentrations were significantly higher in dogs with 
multicentric high-grade lymphoma compared to healthy dogs and dogs with inflammatory 
disease (Fig 3–3). 
 
Correlation between sIL-2r and CD25 expression 
I further examined whether serum sIL-2r concentrations correlated with CD25 expression 
rate of the lymphoma cells. FNA samples from 16 dogs with high-grade B-cell lymphoma 
were subjected to single color FCM.  
Seven of the 16 dogs with high-grade B-cell lymphoma examined had serum sIL-2r 
concentrations detectable by the present ELISA system (n=7, range: 41.8–256.9 ng/ml). In 
the remaining 9 dogs, serum sIL-2r concentration was below the detection limit (25 ng/ml). 
The rates of CD25 expression (mean±SD) in the FNA samples obtained from the 16 dogs 
with high-grade B-cell lymphoma were 47.0±30.4% (n=16, range: 0.4–97.1%). No 
correlation was observed between the serum concentration of sIL-2r and CD25-positive rate 
of lymphoma cells (p=0.68) in dogs with high-grade B-cell lymphoma (Fig 3–4). 
  
Changes of the serum sIL-2r concentrations during the clinical course in dogs with 
lymphoma 
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In order to examine the relationship between the serum sIL-2r concentrations and the 
clinical outcome, I measured the sIL-2r concentrations in comparison to the lymph node sizes 
in 4 dogs with lymphoma that underwent multi-drug chemotherapy (UW-25) (Fig 3–5). 
Case 1 was a 9-year-old Miniature Dachshund with an invasive mass of approximately 10 
cm in diameter in the dorsal muscles which was histopathologically diagnosed as skeletal 
high-grade B-cell lymphoma. The dog was treated with UW-25 protocol and achieved 
complete response (CR) at week 9. CR could be maintained until week 22 (Fig 3–5. A). The 
serum sIL-2r concentration was 60.0 ng/ml before treatment (week 1). In parallel to the 
remission induction, serum sIL-2r level was found to be decreased at week 3 (26.5 ng/ml) 
and week 9 (<25 ng/ml). Low serum sIL-2r concentration under detection limit was 
maintained from week 9 to week 22.  
A 12-year-old Pembroke Welsh Corgi (Case 2) was diagnosed as multicentric high-grade 
B-cell lymphoma and was treated with UW-25 protocol. Response to chemotherapy was 
observed, resulting in CR from week 3 to week 65. At the week 69, relapse with the 
peripheral lymph node enlargement was observed and the 2nd-round UW-25 protocol was 
started (Fig 3–5. B). The sIL-2r level was 31.6 ng/ml before chemotherapy and 31.9 ng/ml at 
week 3. The serum sIL-2r concentration was continuously low below the detection limit from 
week 4 to week 45; however, it increased again at week 56 (34.0 ng/ml) and continued to 
increase until week 69 when the relapse became apparent. 
75 
 
A 9-year-old West Highland White terrier (Case 3) was diagnosed as multicentric 
high-grade B-cell lymphoma. After initiation of treatment with UW-25 protocol, CR was 
achieved at week 10; however, relapse was observed during the treatment protocol at week 11. 
Due to the unresponsiveness to the chemotherapeutic agents used in UW-25 protocol, rescue 
protocols using lomustine and then D-MAC (dexamethasone, melphalan, actinomycin-D, and 
cytosine arabinoside) (Alvarez et al., 2006) were applied, resulting in limited efficacy (Fig 3–
5. C). Because of the resistance to any of the chemotherapies used, Case 3 was euthanized at 
week 30. Serum sIL-2r concentration was 256.9 ng/ml at week 1 before UW-25 and was kept 
at relatively high level ranging from 80.9 to 254.0 ng/ml throughout the observation period. 
Serum sIL-2r concentration was shown to increase at week 3 and week 15 prior to the lymph 
node enlargement at week 5, and week 17, respectively. 
Case 4 was a 9-year-old Border Collie and was diagnosed as multicentric high-grade 
B-cell lymphoma. After starting UW-25 protocol, this case showed CR at week 5. However, 
from week 5 the lymph node size was found to wax and wane until week 15 followed by the 
second CR period from week 17 to week 37. Because progressive disease (PD) was clinically 
apparent at week 41, the 2nd-round UW-25 protocol was started, resulting in PR from week 
43 (Fig 3–5. D). Serum sIL-2r concentration in this case was 68.0 ng/ml before UW-25 and 
gradually increased until week 17. High sIL-2r level was maintained from week 5 to 17 in 
conflict with the small size of lymph node. At week 23 in the CR period, serum sIL-2r 
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concentration was found to decrease to undetectable level (<25 ng/ml). Before the clinical 
relapse at week 41, the serum sIL-2r was found to be increased (77.8 ng/ml) at week 32. 
Serum sIL-2r concentration decreased in parallel to the induction of PR at week 43. 
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Discussion 
 
In dogs, previous studies reported that sIL-2r in bronchoalveolar lavage fluid might serve 
as a significant biological marker in monitoring the immunological status of dogs after lung 
transplantation (Chang et al., 1990, 1991). However, there has been no study to evaluate 
serum sIL-2r concentration in dogs with lymphoma so far because of the lack of specific 
ELISA system. The sandwich ELISA system developed in this study would enable us to 
monitor serum sIL-2r concentration in dogs and evaluate its correlation not only with 
lymphomas evaluated in this study but also other diseases such as various autoimmune and 
inflammatory disorders. 
   The data obtained in this study revealed that the sIL-2r concentrations of dogs with 
multicentric high-grade lymphoma at the initial diagnosis were significantly higher than those 
of healthy dogs and dogs with inflammatory disease. Moreover, it was found that sIL-2r level 
was also elevated in a proportion of dogs with other lymphoma types and immune-mediated 
disease. In humans, elevated serum sIL-2r concentration was observed at diagnosis of the 
several lymphoid malignancies such as HCL, ATL, HL, NHL, cutaneous T-cell lymphoma 
(CTCL), acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL) 
(Bien et al., 2008). Serum sIL-2r concentration was reported to range approximately 100-500 
U/ml (about 330-1,650 pg/ml) in healthy human individuals (Bien et al., 2008), whereas more 
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than 10 times higher in patients with aggressive NHL compared to healthy controls (Stasi et 
al., 1994). Moreover, in human NHL, some studies demonstrated that serum sIL-2r level 
could be an important prognostic factor for NHL (Niitsu et al., 2001; Goto et al., 2005). In 
our ELISA system for canine sIL-2r developed here, the detection limit was at 25 ng/ml, 
which was approximately 100-fold higher than the detection limit in the ELISA system for 
human sIL-2r (Bien et al., 2008). The ELISA system for canine sIL-2r could detect serum 
sIL-2r in only 19 of 51 dogs with lymphoma before chemotherapy and could not be used to 
monitor the change of sIL-2r concentration less than 25 ng/ml. Further study is needed to 
develop a sandwich ELISA system with higher sensitivity by using more appropriate sets of 
capture and detection antibodies through production of mAbs directed to canine CD25. 
In this study, CD25 expression levels on lymphoma cells were variable in high-grade 
B-cell lymphoma. No correlation between serum level of sIL-2r and CD25 positive rate of 
lymphoma cells was observed in dogs with high-grade B-cell lymphoma. In humans, the 
correlation between CD25 expression level on the tumour cells and serum sIL-2r 
concentration has been reported in ATL or T lymphoblastic lymphoma (Yasuda et al., 1988; 
Toji et al., 2015); however, such correlation was not observed in the patients with DLBCL 
(Fujiwara et al., 2013; Toji et al., 2015). Elevated levels of sIL-2r in the serum have been also 
found in some autoimmune or inflammatory diseases (Rubin et al., 1990; Bien et al., 2008). 
Moreover, sIL-2r was reported to be most probably released from activated lymphoid cells 
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infiltrated in the neoplastic tissues (Frydecka et al., 1996). In the present study, serum sIL-2r 
concentration was below the detection limit in most of the dogs with TZL, in which high 
level of CD25 expression was confirmed on lymphoma cells in Chapters 1 and 2 in this thesis. 
These findings indicate the complex mechanism to generate sIL-2r depending upon the 
lymphoma subtypes and other possibilities derived from non-neoplastic lymphoid cells in 
various disorders. 
The precise biological role of sIL-2r in lymphoid malignancies remains controversial. 
Several studies demonstrated suppressed IL-2 level through overexpression of sIL-2r in 
human patients in advanced clinical stages malignancies (De Vita et al., 1998; Olejniczak et 
al., 2008). It has been shown that sIL-2r released from the cell membrane keeps an ability to 
bind IL-2 in humans (Rubin et al., 1985, 1986, 1990). Therefore, some studies suggested that 
disease-related immunosuppression may be mediated by the increased concentration of sIL-2r 
(Heaney et al., 1998). Moreover, some studies in human lymphomas demonstrated that 
patients with higher serum sIL-2r concentration had poorer prognoses or response to therapy 
(Goto et al., 2005; Bien et al., 2008; Hashimoto et al., 2013). Unfavorable influence from the 
sIL-2r remains to be elucidated in the dogs with lymphoma in this study, therefore further 
works to evaluate sIL-2r will be able to disclose its role in various disorders in dogs. 
   In monitoring serum sIL-2r concentrations during the chemotherapy in high-grade B-cell 
lymphoma cases, serum sIL-2r concentration was shown to change in association with the 
80 
 
disease course in the 4 dogs examined. In Cases 2 and 4, sIL-2r level was found to increase 
13 and 9 weeks before relapse, respectively, when clinical CR was still maintained. In 
humans, serial determinations of serum sIL-2r were shown to be useful to predict the relapse 
of malignant lymphoma more than 10 months preceding the relapse (Wakao et al., 2002). 
Moreover, half-life of sIL-2r was estimated to be 0.62 hr (Bien et al., 2008). Kinetics of 
canine sIL-2r could be similar to those of human sIL-2r because of the structural similarities 
of CD25 between the 2 species. The results obtained in this study suggest that serum sIL-2r 
concentration can be used as an early indicator of relapse in canine lymphoma patients at 
least which have high concentration of sIL-2r before treatment. 
In Case 4, high levels of sIL-2r were continuously observed until week 17 despite 
regression of lymph nodes after initiation of chemotherapy. In this case, it might be possible 
that lymphoma cells in several organs in the body other than peripheral lymph nodes caused 
the increase in sIL-2r during the period. Although Case 4 had peripheral lymphadenopathy as 
detected by physical examination, there were enlarged intrathoracic, hepatic and subiliac 
lymph nodes as well as intrasplenic legions revealed by ultrasonography before 
chemotherapy. Sizes of hepatic and subiliac lymph nodes and splenic legion were found to 
increase at week 5 in spite of the decrease in sizes of the peripheral lymph nodes. Increase in 
serum sIL-2r concentrations during the period might reflect the lymphoma lesions in several 
organs in the body. 
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The sandwich ELISA assay developed in this study demonstrated the changes of serum 
sIL-2r concentrations reflecting the growth/regression of lymphoma in dogs as previously 
shown in humans (Wakao et al., 2002). Monitor of sIL-2r levels during the chemotherapy 
would enable us to acquire the predictive information of biological behavior for dogs with 
lymphoma. Using the system developed here, it would be possible to use sIL-2r as a novel 
biological marker of activity of neoplasms in the progression and regression of lymphoma. 
The sIL-2r level can be a candidate marker as an indicator for predicting early relapse and 
assessing treatment efficacy in canine lymphoma. 
   In conclusion, I demonstrated the presence of sIL-2r protein of 45KDa in canine serum 
and constructed a specific sandwich ELISA system for its quantification. Moreover, dogs 
with multicentric high-grade B-cell lymphoma were shown to have high serum sIL-2r level 
before treatment and serum sIL-2r level was found to reflect the tumour cell burden in canine 
lymphoma cases. Although improvement of the sensitivity of the ELISA system is required, 
the present study revealed the possible clinical usefulness to monitor the disease course in 
canine lymphoma. Further studies on the biological role of sIL-2r will contribute to advance 
the clinical monitoring and elucidation of pathophysiology in dogs with lymphoma. 
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Fig 3–1. Immunoblot for detection of CD25 in 3 canine lymphoid cell lines and a serum 
sample from healthy dog. 
Lanes 1 and 5: marker protein; Lanes 2, 3, and 4: cell lysates of canine lymphoid tumour cell 
lines, UL-1, CL-1, and Nody-1, respectively; Lanes 6 and 7: normal dog serum samples 
immunoprecipitated with and without P4A10, respectively. 
Immunoblot was performed by rabbit anti-CD25 antibody (sc-664). 
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Fig 3–2. Linearity of recombinant canine CD25 measured by the sandwich ELISA. 
The dots and error bars represent mean absorbance values and standard deviations,  
respectively. 
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Fig 3–3. Serum sIL-2r levels in healthy dogs, dogs with inflammatory disease, dogs with 
immune-mediated disease and dogs with mutlicentric high-grade lymphoma, mutlicentric 
low-grade lymphoma, alimentary lymphoma, cutaneous lymphoma, splenic lymphoma, 
mediastinal lymphoma, and skeletal lymphoma before chemotherapy. 
The dotted line indicates detection limit for sIL-2r in the ELISA (25 ng/ml). 
*: p < 0.05, The Mann-Whitney rank sum test.  
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Fig 3–4. Correlation between serum sIL-2r concentration and CD25-positive rate of 
lymphoma cells in FNA samples from dogs with multicentric high-grade B-cell 
lymphoma. The dotted line indicates detection limit for sIL-2r in this ELISA (25 ng/ml). 
Spearman's rank correlation coefficient. 
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Fig 3–5. Changes in the serum sIL-2r concentrations and total lymph node volumes at several 
time points in 4 dogs with high-grade lymphoma. The closed and open circles indicate serum 
sIL-2r concentration and mass or lymph node sizes, respectively, in Case 1 (A), Case 2 (B), 
Case 3 (C), and Case 4 (D).  
The dotted line indicates detection limit for sIL-2r (25 ng/ml). The period of chemotherapy 
protocol is indicated with the open columns below the graphs. The numbers of weeks after 
the initiation of chemotherapy are indicated below the graphs.  
UW-25: University of Wisconsin 25-week chemotherapy protocol, Rescue: rescue protocols 
including the administration of lomustine, dexamethasone, melphalan, actinomycin-D, and 
cytosine arabinoside. 
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Added rcCD25 Observed sIL-2r Recovery
(ng/ml) (ng/ml) (%)
0 35.19
1 29.21 62.63 97
66.59 107.85 106
0 99.86
2 29.21 130.56 101
66.59 169.88 102
0 102.12
3 29.21 138.05 105
66.59 188.69 112
Sample No.
Table 3–1. Spiking recovery of the sandwich ELISA for canine sIL-2r using 3 dog serum 
samples. 
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Variability Sample 1 Sample 2 Sample 3
   Mean (ng/ml) 148.09 74.86 33.66
   Standard deviation (ng/ml) 5.44 1.99 0.26
Intra-assay variability
   Number of repeats 5 5 5
   Coefficient of variation (%) 4.75 5.39 12.9
Inter-assay variability
   Number of repeats 3 3 3
   Coefficient of variation (%) 3.67 2.66 0.76
 
Table 3–2. Intra-assay and inter-assay variability in the sandwich ELISA for canine sIL-2r for 
3 serum samples. 
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Conclusion 
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A series of studies in this thesis were carried out to investigate the biological role of the 
expression of interleukin-2 receptor alpha chain (CD25) in tumour cells and serum soluble 
interleukin-2 receptor (sIL-2r) in dogs with lymphoma for the future development of the 
clinically applicable diagnostic and therapeutic modalities.  
T-zone lymphoma (TZL) was found to be a new subtype in canine lymphoma, which had 
an indolent clinical course, after publication of the World Health Organization (WHO) 
classification of hematopoietic tumours of domestic animals in 2002 (Valli et al., 2002). 
There has been no criteria to indicate optimal treatment approach to this specific subtype of 
canine lymphoma. First, the study in Chapter 1 of the present thesis was conducted to 
understand the clinical and histopathological features and evaluate CD25 expression in 16 
dogs with TZL, which is a common histopathological subtype of canine indolent lymphoma. 
TZL was commonly diagnosed in Golden Retrievers and Shih Tzu of relatively older age. At 
initial examination, generalized lymphadenopathy was found in all dogs, and peripheral 
lymphocytosis was found in 10 of the 16 dogs. At initial diagnosis or during the disease 
course, 8 dogs (50%) were affected with demodicosis. Immunohistochemical analysis for 
CD3, CD20, and CD25 was performed for 6 dogs with TZL; the tumor cells were positive for 
CD3 and CD25 and negative for CD20. Median overall survival time was 938 days and only 
3 cases (19%) with TZL experienced the death from lymphoma at the end of the follow-up 
duration. A watchful waiting approach was adopted for 6 cases (38%), and 5 of the 6 dogs 
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were still alive at the end of follow-up. The occurrence of infectious diseases including 
demodicosis might be due to the immunosuppression mediated by TZL with abundant 
expression of CD25. 
CD25 expression has been reported in various human lymphoid tumours (Sheibani et al., 
1987; Tesch et al., 1993; Burton et al., 1994; Nakase et al., 1994a, b; Horiuchi et al., 1997; 
Fujiwara et al., 2013, 2014) and suggested to correlate with their prognoses. Based on the 
results obtained in the study in Chapter 1, I investigated the expression of CD25 in various 
types of canine lymphoid tumours and explored its influence on the prognosis in dogs with 
high-grade B-cell lymphoma in Chapter 2. Immunohistochemical analyses of the tissues from 
diffuse large B-cell lymphoma (DLBCL) (n=6), T-zone lymphoma (TZL) (n=5), and 
follicular lymphoma (FL) (n=2) revealed that intense CD25 expression was observed in 
accordance with lymphoma cell localization. CD25 expression was detected in all of the TZL 
and FL cases, while it was variable among DLBCL cases. Furthermore, I evaluated CD25 
expression in tumour cells by flow cytometric analysis in 29 dogs with lymphoid 
malignancies, including high-grade B-cell lymphoma (n=17), TZL (n=5), FL (n=2), 
cutaneous lymphoma (n=2), and acute lymphoblastic leukaemia (ALL) (n=3). CD25 
expression was significantly higher in dogs with high-grade B-cell lymphoma or TZL than 
that in healthy dogs. In prognostic analysis of 15 cases with high-grade B-cell lymphoma, the 
progression-free survival was significantly shorter in CD25-high group than that in 
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CD25-low group. The results obtained in this study would be useful for subtype 
differentiation and future development of molecular-targeted therapy directed to CD25. From 
the results obtained in Chapters 1 and 2, CD25 expression was suspected to have an impact 
on the biological behaviour of the lymphoid malignancy and immune response of the dog 
patients. Based on the results obtained in Chapters 1 and 2, I speculated that soluble form of 
CD25 could be released from the canine lymphoma cells as with the lymphoid malignancies 
in humans. Thus, in Chapter 3, I examined the presence of soluble interleukin-2 receptor 
(sIL-2r) in canine serum and quantified its concentration using a newly developed sandwich 
enzyme-linked immunosorbent assay (ELISA). Using immunoprecipitation (IP) assay, CD25 
protein weighing approximately 45 KDa was detected in canine serum, which was obviously 
smaller than the membrane-bound CD25 (approximately 55KDa). I constructed a new 
sandwich ELISA system to quantify the level of sIL-2r in dog sera. The serum sIL-2r 
concentration was significantly higher in dogs with multicentric high-grade B-cell lymphoma 
before treatment than that in healthy dogs and dogs with inflammatory disease at the initial 
diagnosis. Serum sIL-2r concentration was also found to be elevated in a small proportion of 
the dogs affected with other lymphoma types and dogs with immune-mediated disease. The 
present study indicated no correlation between sIL-2r concentration in serum and 
CD25-positive rate of lymphoma cells in dogs with high-grade B-cell lymphoma. Changes in 
serum sIL-2r level during the clinical course generally paralleled with the changes of lymph 
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node size in dogs with high-grade B-cell lymphoma. The sIL-2r level decreased along with 
the remission induction therapy by CHOP-based protocol. Increase in sIL-2r concentration 
was found 9 to 13 weeks before the relapse. Increase of sIL-2r concentration was considered 
to be an indication for the restart of the remission induction therapy even in the clinical 
remission. The results in Chapter 3 indicated that the sIl-2r concentration could be a marker 
as an indicator for predicting early relapse, and assessment of treatment efficacy in canine 
lymphoma. 
Lymphoma is one of the most common neoplastic diseases in dogs and it arises in various 
anatomical locations. Combination chemotherapy is generally used as a standard therapeutic 
strategy for canine lymphoma and can induce remission in a large proportion of the cases; 
however, most dogs eventually experience relapse with frequent acquisition of drug 
resistance. Findings obtained through a series of the studies in this thesis will contribute to an 
adjunct to the diagnosis, subtype differentiation, and assessment of tumour progression in 
canine lymphomas. Moreover, in a future prospect, development of molecular-targeted 
therapy directed to CD25 and more effective chemotherapy protocol by employing the sIL-2r 
monitoring system will lead to the improvement of the treatment outcome in canine 
lymphoma. 
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